87 related articles for article (PubMed ID: 8951192)
41. Erythrocyte nucleoside transport: asymmetrical binding of nitrobenzylthioinosine to nucleoside permeation sites.
Jarvis SM; McBride D; Young JD
J Physiol; 1982 Mar; 324():31-46. PubMed ID: 7097603
[TBL] [Abstract][Full Text] [Related]
42. Nitrobenzylthioinosine binding cooperativity in chromaffin tissue membranes.
Casillas T; Sen RP; Delicado EG; Miras-Portugal MT
Rev Esp Fisiol; 1992 Mar; 48(1):1-6. PubMed ID: 1410764
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.
Groll AH; Mickiene D; Petraitiene R; Petraitis V; Lyman CA; Bacher JS; Piscitelli SC; Walsh TJ
Antimicrob Agents Chemother; 2001 Oct; 45(10):2845-55. PubMed ID: 11557479
[TBL] [Abstract][Full Text] [Related]
44. Ticagrelor Does Not Inhibit Adenosine Transport at Relevant Concentrations: A Randomized Cross-Over Study in Healthy Subjects In Vivo.
van den Berg TN; El Messaoudi S; Rongen GA; van den Broek PH; Bilos A; Donders AR; Gomes ME; Riksen NP
PLoS One; 2015; 10(10):e0137560. PubMed ID: 26509673
[TBL] [Abstract][Full Text] [Related]
45. Adenosine receptors and the nucleoside transporter in human brain vasculature.
Kalaria RN; Harik SI
J Cereb Blood Flow Metab; 1988 Feb; 8(1):32-9. PubMed ID: 3339106
[TBL] [Abstract][Full Text] [Related]
46. Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes.
van Griensven JM; Jusko WJ; Lemkes HH; Kroon R; Verhorst CJ; Chiang ST; Cohen AF
Clin Pharmacol Ther; 1995 Dec; 58(6):631-40. PubMed ID: 8529328
[TBL] [Abstract][Full Text] [Related]
47. Inactivation of the nucleoside transporter of the human erythrocyte by dimethyl (2-hydroxy-5-nitrobenzyl) sulphonium bromide.
Thorne SD; Lowe AG
Biochem Soc Trans; 1991 Nov; 19(4):418S. PubMed ID: 1794543
[No Abstract] [Full Text] [Related]
48. Interaction of [3H]dilazep at nucleoside transporter-associated binding sites on S49 mouse lymphoma cells.
Gati WP; Paterson AR
Mol Pharmacol; 1989 Jul; 36(1):134-41. PubMed ID: 2747624
[TBL] [Abstract][Full Text] [Related]
49. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
[TBL] [Abstract][Full Text] [Related]
50. Unexpected relationship between plasma protein binding and the pharmacodynamics of 2-NAP, a CCK1-receptor antagonist.
Gerskowitch VP; Hodge J; Hull RA; Shankley NP; Kalindjian SB; McEwen J; Black JW
Br J Clin Pharmacol; 2007 May; 63(5):618-22. PubMed ID: 17052250
[TBL] [Abstract][Full Text] [Related]
51. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
52. Bioanalyses and pharmacokinetics of nafronyl in the dog.
Garrett ER
J Pharm Sci; 1984 May; 73(5):635-49. PubMed ID: 6737238
[TBL] [Abstract][Full Text] [Related]
53. Plasma and red blood cell pharmacokinetics of pimobendan enantiomers in healthy Chinese.
Chu KM; Shieh SM; Hu OY
Eur J Clin Pharmacol; 1995; 47(6):537-42. PubMed ID: 7768258
[TBL] [Abstract][Full Text] [Related]
54. Dabigatran pharmacokinetic-pharmacodynamic in sheep: Informing dose for anticoagulation during cardiopulmonary bypass.
Eaton MP; Nadtochiy SM; Stefanos T; Anderson BJ
Perfusion; 2024 Jan; ():2676591231226291. PubMed ID: 38171494
[TBL] [Abstract][Full Text] [Related]
55. In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood.
Bongard HJ; Pluim D; Waardenburg RC; Ravic M; Beijnen JH; Schellens JH
Anticancer Drugs; 2003 Jul; 14(6):405-10. PubMed ID: 12853880
[TBL] [Abstract][Full Text] [Related]
56. A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam.
Zandvliet AS; Schellens JH; Copalu W; Beijnen JH; Huitema AD
J Pharmacokinet Pharmacodyn; 2006 Oct; 33(5):543-70. PubMed ID: 16946998
[TBL] [Abstract][Full Text] [Related]
57. Whole blood or plasma: what is the ideal matrix for pharmacokinetic-driven drug candidate selection?
Dash RP; Veeravalli V; Thomas JA; Rosenfeld C; Mehta N; Srinivas NR
Future Med Chem; 2021 Jan; 13(2):157-171. PubMed ID: 33275044
[TBL] [Abstract][Full Text] [Related]
58. Characterization of pharmacodynamic recession slopes for direct and indirect response models.
Krzyzanski W; Jusko WJ
J Pharmacokinet Biopharm; 1998 Aug; 26(4):409-36. PubMed ID: 10214560
[TBL] [Abstract][Full Text] [Related]
59. Preclinical investigation of the pharmacokinetics, metabolism, and protein and red blood cell binding of DRDE-07: a prophylactic agent against sulphur mustard.
Verma P; Vijayaraghavan R
Acta Pharm Sin B; 2014 Oct; 4(5):394-401. PubMed ID: 26579409
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetics of haloalkylamines: cyclization and distribution in blood in vitro and in vivo.
Ross SB
J Pharm Pharmacol; 1975 May; 27(5):322-8. PubMed ID: 239132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
